Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Assets (2016 - 2026)

Ani Pharmaceuticals' Assets history spans 16 years, with the latest figure at $1.4 billion for Q4 2025.

  • On a quarterly basis, Assets rose 12.14% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 12.14% increase, with the full-year FY2025 number at $1.4 billion, up 12.14% from a year prior.
  • Assets hit $1.4 billion in Q4 2025 for Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Over the last five years, Assets for ANIP hit a ceiling of $1.4 billion in Q4 2025 and a floor of $463.8 million in Q1 2021.
  • Historically, Assets has averaged $924.6 million across 5 years, with a median of $874.6 million in 2023.
  • The widest YoY moves for Assets: up 67.31% in 2021, down 3.81% in 2021.
  • Tracing ANIP's Assets over 5 years: stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then increased by 18.99% to $904.4 million in 2023, then skyrocketed by 42.02% to $1.3 billion in 2024, then rose by 12.14% to $1.4 billion in 2025.
  • Business Quant data shows Assets for ANIP at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.